Journal article icon

Journal article

CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis

Abstract:
The basis of immune evasion, a hallmark of cancer, can differ even when cancers arise from one cell type such as in the human skin keratinocyte carcinomas: basal and squamous cell carcinoma. Here we showed that the basal cell carcinoma tumor initiating cell surface protein CD200, through ectodomain shedding, was responsible for the near absence of NK cells within the basal cell carcinoma tumor microenvironment. In situ, CD200 underwent ectodomain shedding by metalloproteinases MMP3 and MMP11, which released biologically active soluble CD200 into the basal cell carcinoma microenvironment. CD200 bound its cognate receptor on NK cells, to suppress MAPK pathway signaling that in turn blocked indirect (gamma interferon release) and direct cell killing. In addition, reduced ERK phosphorylation relinquished negative regulation of PPARγ regulated gene transcription and lead to membrane accumulation of the Fas/FADD death receptor and its ligand, FasL that resulted in activation-induced apoptosis. Blocking CD200 inhibition of MAPK or PPARγ signaling restored NK cell survival and tumor cell killing, with relevance to many cancer types. Our results thus uncover a paradigm for CD200 as a potentially novel and targetable NK cell specific immune checkpoint, which is responsible for NK cell associated poor outcomes in many cancers
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Authors

More by this author
Role:
Author
ORCID:
0000-0002-4542-7572
More by this author
Role:
Author
ORCID:
0000-0001-8169-0776
More by this author
Role:
Author
ORCID:
0000-0002-3160-5120
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-1826-953X
More by this author
Role:
Author
ORCID:
0000-0002-4108-5632


More from this funder
Funder identifier:
10.13039/501100000289
Grant:
Development fund
More from this funder
Funder identifier:
10.13039/501100000296
Grant:
6056i
More from this funder
Funder identifier:
10.13039/501100014332
Grant:
Ser Cymru award


Publisher:
American Society for Clinical Investigation
Journal:
The Journal of Clinical Investigation More from this journal
Volume:
132
Issue:
21
Pages:
e150750
Article number:
e150750
Publication date:
2022-09-08
DOI:
EISSN:
1558-8238
ISSN:
0021-9738


Language:
English
Keywords:
Pubs id:
1279420
Local pid:
pubs:1279420
Source identifiers:
W4294991249
Deposit date:
2026-04-28
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP